To me the cardiovascular protection is remarkable, treating such pts, if it can be replicated in humans, it will be a massive game changer for early treatment. As (i forgot the CEOs name) stated in the video, due to the large pt cohort it could potential treat, the company would not able to undertake a phase 3 study (sadly), therefore would be out licenced. Given its acute use, you could see this in the pre hospital and emergency settings.
Than the neurological protection is again another game changer, especially as the population is getting older and people are living longer.
TBI treatment could also be used in the prehospotal and emergency phase, thankfully TBIs are not as frequent as cardiac and neurological injuries.
NYR Price at posting:
9.3¢ Sentiment: Buy Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)